Combining the POx-Mannose nanovaccine with pexidartinib, which is a modulator of the TAM function, effectively restricts MC38 tumor growth and synergizes with PD-1 blockade to control MC38 and CT26 tumor growth and improve survival, as further validated in the B16F10 melanoma model. This evidence concerns the gene PDCD1 and neoplasm.